Novavax | 8-K: Investor Presentation
Novavax | 3: Initial statement of beneficial ownership of securities-Officer Draghia-Akli Ruxandra
Novavax | 4: Statement of changes in beneficial ownership of securities-Officer Draghia-Akli Ruxandra
Novavax | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(9.63%)
Novavax | 10-Q: Q3 2024 Earnings Report
Novavax | 8-K: U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
Novavax | 8-K: Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights
Novavax | 8-K: Settlement Agreement
Novavax | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(9.63%)
Novavax | 8-K: Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
Novavax | 8-K: Regulation FD Disclosure
Novavax | 144: Notice of proposed sale of securities pursuant to Rule 144
Novavax | 4: Statement of changes in beneficial ownership of securities-Officer Trizzino John
Novavax | 4: Statement of changes in beneficial ownership of securities-Officer Kelly James Patrick
Novavax | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Novavax | 8-K: Novavax Reports Second Quarter 2024 Financial Results and Operational Highlights
Novavax | 10-Q: Q2 2024 Earnings Report
Novavax | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-STATE STREET CORPORATION(4.32%)
Novavax | 4: Statement of changes in beneficial ownership of securities-Director YOUNG JAMES F
Novavax | 4: Statement of changes in beneficial ownership of securities-Director YOUNG JAMES F
No Data
No Data